Herpes Simplex Virus Infection Treatment Market

Herpes Simplex Virus Infection is commonly known as herpes. The two types of herpes simplex virus (HSV) are HSV-1 (known to cause orofacial disease such as cold sores) and HSV-2 (causes genital infections). Over 80% of herpes infections is asymptomatic. Symptomatic infections are presented with blistering sores, pain during urination, swollen lymph nodes, and fever. The period of latency and mode of reactivation of HSV is still unclear.

Herpes Simplex Virus Infection Treatment Market contains market size and forecasts of Herpes Simplex Virus Infection Treatment in Global, including the following market information:

Global Herpes Simplex Virus Infection Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Herpes Simplex Virus Infection Treatment market was valued at 4673.6 million in 2021 and is projected to reach US$ 5529.3 million by 2028, at a CAGR of 2.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

By Type Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Herpes Simplex Virus Infection Treatment include F. Hoffmann-La Roche Ltd, Sanofi, Teva Pharmaceuticals Inc, Merck & Co., Inc, Apotex Inc, Viatris, Epi Health LLC, Zydus Pharmaceuticals and GlaxoSmithKline LLC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Herpes Simplex Virus Infection Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Herpes Simplex Virus Infection Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Herpes Simplex Virus Infection Treatment Market Segment Percentages, by Type, 2021 (%)

By Type

Herpes Simplex Virus-1 (HSV-1) Infection

Herpes Simplex Virus-2 (HSV-2) Infection

HSV1 & HSV2 Co-infection

By Route of Administration

Oral

Parenteral

By Drug Molecule

Small Molecule

Vaccine

Global Herpes Simplex Virus Infection Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Herpes Simplex Virus Infection Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Herpes Simplex Virus Infection Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Herpes Simplex Virus Infection Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Herpes Simplex Virus Infection Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Herpes Simplex Virus Infection Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

F. Hoffmann-La Roche Ltd

Sanofi

Teva Pharmaceuticals Inc

Merck & Co., Inc

Apotex Inc

Viatris

Epi Health LLC

Zydus Pharmaceuticals

GlaxoSmithKline LLC

Carlsbad Tech

Avet Pharmaceuticals Inc

Glenmark Pharmaceuticals

Fresenius Kabi

Agenus, Inc

Maruho Co. Ltd

AiCuris Anti-infective Cures GmbH